14 Nov

How Novartis’s Cosentyx Is Positioned after 3Q17

WRITTEN BY Daniel Collins

Cosentyx revenue trends

In 3Q17, Novartis’s (NVS) Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ (quarter-over-quarter).

How Novartis’s Cosentyx Is Positioned after 3Q17

Future 5 trial

In November 2017, Novartis presented the results from its Future 5 trial, wherein Cosentyx demonstrated a reduction in signs and symptoms of psoriatic arthritis (or PsA) and substantial inhibition in the progression of joint structural damage in individuals with PsA compared with placebo therapy.

In the Future 5 trial, 996 participants were randomized to receive Cosentyx 300 mg (milligrams) with a loading dose (or LD), Cosentyx 150 mg with LD, and Cosentyx 150 mg without LD. Patients receiving Cosentyx demonstrated substantial progress in the signs and symptoms of PsA, according to the American College of Rheumatology (or ACR), with response criteria of 20% improvement (ACR20) at 16 weeks.

By comparison, Eli Lilly’s (LLY) Taltz, Amgen’s (AMGN) Enbrel, and Johnson & Johnson’s (JNJ) Stelara reported revenues of ~$151.3 million, ~$1.4 billion, and ~$1.1 billion, respectively, in 3Q17. Notably, the Vanguard FTSE All-World ex-US ETF (VEU) invests ~0.67% of its total portfolio holdings in Novartis.

Latest articles

After remaining tepid for the first four months of the year, gold prices have taken off in a big way. The initial impetus was provided by a tweet made by President Donald Trump on May 5, which revived trade tensions in a big way.

20 Jun

How Are Charter’s Revenues Trending in 2019?

WRITTEN BY Ambrish Shah

In the first quarter, Charter Communications (CHTR) reported total revenues of $11.2 billion—a rise of 5.2% year-over-year and $7 million ahead of the consensus estimate.

This morning before the market opened, Tesla (TSLA) was trading on a negative note despite a sharp rise in index futures. As of 9:10 AM ET, Tesla stock had fallen 1.2% in the pre-market session to $234.74 after Goldman Sachs cut the target price on the company by about 21%.

The US-China trade war has already given a scare to Apple’s (AAPL) investors vis-à-vis the possibility of a 25% tariff on Apple goods being imported from its Chinese facilities. As a result, Apple might be considering shifting its plants out of China.

Yesterday, Greenlane Holdings (GNLN) fell a whopping 17.1%. The stock has now fallen 28% this month, and it hit its all-time low yesterday. Greenlane Holdings listed in April and priced its IPO at $17 per share. However, since the stock surged more than 25% after its listing, it has been a sorry story for Greenlane Holdings investors.

Yesterday, Mexico ratified the USMCA. The agreement was negotiated last year and would replace the 25-year-old NAFTA. The United States and Canada are yet to ratify the agreement. Renegotiating NAFTA was among Trump’s prominent campaign promises.